ClinicalTrials.Veeva

Menu
J

Jodha Tishon | Toronto, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Daridorexant
TAK-994
ACT-541468
E2086
Atomoxetine
FT218
Solriamfetol
Aripiprazole
Vortioxetine
Aroxybutynin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 12 total trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

The primary purpose of this study is to evaluate the efficacy of single oral doses of E2086 compared to placebo in the treatment of excessive daytime...

Enrolling
Narcolepsy Type 1 (NT1)
Drug: Active Comparator Placebo
Drug: E2086 Placebo

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

Trial sponsors

Idorsia Pharmaceuticals logo
Takeda logo
Apnimed logo
A
Axsome Therapeutics logo
Eisai logo
Janssen (J&J Innovative Medicine) logo
Lundbeck logo
Otsuka logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems